pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Orencia
drug
save

abatacept

Marketedupdated 3mo ago
by Bristol-Myers Squibb Co
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • drugImmunology1 co-mentions · 1 sources
  • companyUniversity of Thessaly1 co-mentions · 1 sources
  • tagImmunology1 co-mentions · 1 sources
  • tagRheumatoid Arthritis1 co-mentions · 1 sources

indications

investigational
Rheumatoid Arthritis

all catalysts(1)

phase 3 initiation · 1
Apr 27, 2026
phase 3 initiation
4mo ago
University of Thessaly — abatacept (Phase III Trial Initiation)
abatacept
→

Trials studying abatacept

  • phase1Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjectscompletedn=300
  • phase2Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxisrecruitingn=160
  • phase1Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantationrecruitingn=41
  • phase2A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantationrecruitingn=358
  • phase2Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplantactive not recruitingn=30
  • phase2Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Diseaserecruitingn=38
  • phase2Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantationcompletedn=43
  • phase3Abatacept in Immune Checkpoint Inhibitor Myocarditisrecruitingn=390
more trials →

News(3)

  • An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
    In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
    biopharma_dive · 8d ago
  • BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
    Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
    biospace · 12d ago
  • Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
    Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
    biopharma_dive · 3mo ago
brand
Orencia
generic
abatacept
indication
Graft Versus Host Disease (GVHD)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 13m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?